Provectus Biopharmaceuticals, Inc. (PVCT)
USD 0.13
(-0.76%)
USD 0.13
(-0.76%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 557.71 Thousand | 989.04 Thousand | - | - | - | - |
| Cost of Revenue | 1.69 Million | 63.77 Thousand | 94.12 Thousand | 315.36 Thousand | 756.36 Thousand | 685.21 Thousand |
| Gross Profit | -1.14 Million | 925.26 Thousand | -94.12 Thousand | -315.36 Thousand | -756.36 Thousand | -685.21 Thousand |
| Operating Expenses | 1.75 Million | 3.39 Million | 4.63 Million | 4.93 Million | 6.16 Million | 8.02 Million |
| Selling, General and Administrative Expenses | 1.35 Million | 2.02 Million | 2.05 Million | 2.14 Million | 2.29 Million | 3.3 Million |
| Research and Development Expenses | 1.74 Million | 2.38 Million | 2.6 Million | 2.81 Million | 4 Million | 4.74 Million |
| Other Expenses | -1.34 Million | -1.02 Million | -27.09 Thousand | -25.65 Thousand | -134.08 Thousand | -26.32 Thousand |
| Cost and Expenses | 3.45 Million | 3.39 Million | 4.63 Million | 4.93 Million | 6.16 Million | 8.02 Million |
| Operating Income | -2.9 Million | -3.42 Million | -4.67 Million | -4.96 Million | -6.29 Million | -8 Million |
| Interest Expense | 216.21 Thousand | 163.69 Thousand | 961.7 Thousand | 1.74 Million | 1.45 Million | 969.71 Thousand |
| Income Tax Expense | - | -433.00 | 961.7 Thousand | 1.74 Million | 1.45 Million | -825 Thousand |
| Earnings before Tax | -3.1 Million | -3.55 Million | -5.53 Million | -6.67 Million | -6.92 Million | -8.15 Million |
| Net Income | -3.1 Million | -3.55 Million | -6.5 Million | -8.42 Million | -8.37 Million | -8.15 Million |
| Earnings Per Share Basic | -0.01 | -0.01 | -0.02 | -0.02 | -0.02 | -0.02 |
| Earnings Per Share Diluted | -0.01 | -0.01 | -0.02 | -0.02 | -0.02 | -0.02 |
| Weighted Average Shares Outstanding | 419.5 Million | 419.47 Million | 408.22 Million | 393.25 Million | 386.59 Million | 382.33 Million |
| Weighted Average Shares Outstanding (Diluted) | 419.5 Million | 419.47 Million | 408.22 Million | 393.25 Million | 386.59 Million | 382.33 Million |
| Gross Margin | -2.05 | 0.94 | - | - | - | - |
| EBIT Margin | -5.19 | -3.42 | - | - | - | - |
| Profit Margin | -5.56 | -3.59 | - | - | - | - |
| EBITDA | -2.89 Million | -3.36 Million | -4.51 Million | -4.64 Million | -5.48 Million | -7.34 Million |
| Earnings Before Tax Margin | -5.20 | -3.47 | - | - | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 254.99 Thousand | 238.07 Thousand | 557.71 Thousand | 121.11 Thousand | 69.73 Thousand | 161.84 Thousand |
| Cost of Revenue | 2230.00 | 2231.00 | 8921.00 | 2230.00 | 2230.00 | 13.43 Thousand |
| Gross Profit | 252.76 Thousand | 235.84 Thousand | 548.78 Thousand | 118.88 Thousand | 67.5 Thousand | 148.4 Thousand |
| Operating Expenses | 911.31 Thousand | 506.43 Thousand | 3.47 Million | 723.56 Thousand | 783.88 Thousand | 784.23 Thousand |
| Selling, General and Administrative Expenses | 440.15 Thousand | -47.33 Thousand | - | 309.49 Thousand | 433.08 Thousand | 527.64 Thousand |
| Research and Development Expenses | 471.16 Thousand | 553.77 Thousand | - | 414.07 Thousand | 350.79 Thousand | 434.21 Thousand |
| Other Expenses | -326.96 Thousand | - | - | 204.28 Thousand | - | - |
| Cost and Expenses | 913.54 Thousand | 508.66 Thousand | 3.48 Million | 725.79 Thousand | 783.88 Thousand | 784.23 Thousand |
| Operating Income | -658.56 Thousand | -270.59 Thousand | -2.92 Million | -604.69 Thousand | -775.83 Thousand | -800.2 Thousand |
| Interest Expense | 61.29 Thousand | 56.77 Thousand | -216.21 Thousand | 58.62 Thousand | -61.52 Thousand | 50.82 Thousand |
| Income Tax Expense | -9301.00 | -1.00 | -15.69 Thousand | 102.00 | -2230.00 | 15.96 Thousand |
| Earnings before Tax | -856.14 Thousand | -504.04 Thousand | -3.11 Million | -663.31 Thousand | -775.83 Thousand | -835.06 Thousand |
| Net Income | -846.84 Thousand | -504.04 Thousand | -3.1 Million | -663.41 Thousand | -775.83 Thousand | -835.06 Thousand |
| Earnings Per Share Basic | -0.00 | -0.00 | - | -0.00 | -0.00 | -0.00 |
| Earnings Per Share Diluted | -0.00 | -0.00 | - | -0.00 | -0.00 | -0.00 |
| Weighted Average Shares Outstanding | 419.52 Million | 419.52 Million | 419.5 Million | 419.52 Million | 419.51 Million | 419.49 Million |
| Weighted Average Shares Outstanding (Diluted) | 419.52 Million | 419.52 Million | 419.5 Million | 419.52 Million | 419.51 Million | 419.49 Million |
| Gross Margin | 0.99 | 0.99 | 0.98 | 0.98 | 0.97 | 0.92 |
| EBIT Margin | -2.57 | -1.13 | - | -4.97 | -11.13 | -4.83 |
| Profit Margin | -3.32 | -2.12 | -5.56 | -5.48 | -11.13 | -5.16 |
| EBITDA | -656.33 Thousand | -268.36 Thousand | - | -602.46 Thousand | -775.83 Thousand | -782 Thousand |
| Earnings Before Tax Margin | -2.58 | -1.14 | -5.25 | -4.99 | -11.13 | -4.94 |
BIOVIC-B
EDRWY
GBK
BEWFF
8433
PLT